A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.

By D. Needham, G. Anyarambhatla, G. Kong, Mark W. Dewhirst. Cancer Research, 2000

769 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5b0e5333364036488160fd55f199426511e43fce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “, thermosensitive liposomal doxorubicin, ThermoDox R ) appears to be the most promising to date (Needham et al., 2000).”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “In comparison, non-temperature-sensitive liposomes also showed some antitumor activity at 42°C (Needham et al., 2000).”
Advances and Challenges of Liposome Assisted Drug Delivery (2015, background): “Of these strategies, the use of an external hyperthermic trigger to release therapeutic compounds from liposomal formulations (e.g., ThermoDox R©) appears to be the most promising to date (Needham et al., 2000).”
Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, methodology): “Advances to liposome design have also been made with the addition of polyethylene glycol (PEG, known as stealth liposomes), which increases circulation time, as well as strategies for a triggered release of the drug once internalized, such as hyperthermia, as is used in ThermoDox®, which is currentl”
Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy (2011, unknown): “In vitro release studies, monopalmitoylphosphatidylcholine-containing TSLs released about 45% of encapsulated doxorubicin in bovine serum at 42°C in a few seconds (20 seconds), while pure DPPC liposomes released only 20% over 1 hour.(79) Banno et al demonstrated that the presence of MSPC, rather tha”
Nanotechnology: Intelligent Design to Treat Complex Disease (2006, background): “proposed recently by incorporating lysophospholipids in the liposomal membrane in gel phase (87,88).”